Expanded HIV testing in low-prevalence, high-income countries: A cost-effectiveness analysis for the United Kingdom

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Long, Elisa F ^a   Mandalia, Roshni ^b   Mandalia, Sundhiya ^b   Alistar, Sabina S ^c   Beck, Eduard J ^b,d   Brandeau, Margaret L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Co ordinating and Analytic Centre National Prospective Monitoring System HIV Health economics Collaboration ^*  (United Kingdom)

^c Stanford University   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HIGH INCOME COUNTRY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MALE; PREVALENCE; QUALITY OF LIFE; SEXUAL BEHAVIOR; SOCIAL STATUS; UNITED KINGDOM; VIRUS TRANSMISSION; ADULT; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; ECONOMICS; EPIDEMIOLOGY; HIV INFECTIONS; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; FALSE POSITIVE REACTIONS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84899767703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095735     Document Type: Article

References (85)

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
2. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
3. Wagner BG, Blower S (2012) Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One 7: e41212.
4. Bärnighausen T, Bloom DE, Humair S (2012) Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A 109: 21271-21276.
5. Long EF, Brandeau ML, Owens DK (2010) The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153: 778-789.
6. Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, et al. (2010) Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One 5: e13132.
7. Health Protection Agency (2012) HIV in the United Kingdom: 2012 Report. Health Protection Report. London, UK: Health Protection Agency.
8. Phillips AN, Cambiano V, Nakagawa F, Brown A, Lampe F, et al. (2013) Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 8: e55312.
9. Rice BD, Elford J, Yin Z, Delpech VC (2012) A new method to assign country of HIV infection among heterosexuals born abroad and diagnosed with HIV. AIDS 26: 1961-1966.
10. Public Health England (2013) HIV Epidemiology in London, 2011 Data. London: Personal communication.
11. Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, et al. (2011) The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One 6: e27830.
12. British HIV Association, British Association for Sexual Health and HIV and British Infection Society (2008) UK National Guidelines for HIV Testing 2008. London, UK: British HIV Association.
13. Health Protection Agency (2012) Evidence and Resources to Commission Expanded HIV Testing in Priority Medical Services in High Prevalence Areas. Health Protection Report. London, UK: Health Protection Agency.
14. National Institute for Health and Clinical Excellence (2011) Increasing the Uptake of HIV Testing to Reduce Undiagnosed Infection and Prevent Transmission Among Black African Communities Living in England. NICE Public Health Guidance. London, UK: National Institute for Health and Clinical Excellence.
15. National Institute for Health and Clinical Excellence (2011) Increasing the Uptake of HIV Testing to Reduce Undiagnosed Infection and Prevent Transmission Among Men Who Have Sex with Men. NICE Public Health Guidance. London, UK: National Institute for Health and Clinical Excellence.
16. Health Protection Agency (2010) Time to Test for HIV: Expanded Healthcare and Community HIV Testing in England. London, UK: Health Protection Agency.
17. Tweed E, Hale A, Hurrelle M, Smith R, Delpech V, et al. (2010) Monitoring HIV testing in diverse healthcare settings: results from a sentinel surveillance pilot study. Sex Transm Infect 86: 360-365.
18. The Lancet Editorial (2009) The UK's appalling failure to tackle HIV. Lancet 373: 1820.
19. Brown A, Gill O, Delpech V (2013) HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med 14: 563-570.
20. Brennan VK, Beard SM, Nangalia M, Hill C (2011) The Case for Universal Testing for HIV in the UK. Gilead Best Practice Sharing Event. London, UK.
21. Long EF, Brandeau ML, Owens DK (2009) Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine 27: 5402-5410.
22. Long EF, Stavert RR (2013) Portfolios of biomedical HIV interventions in South Africa: A cost-effectiveness analysis. J Gen Intern Med 28: 1294-1301.
23. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy. New Engl J Med 352: 32-47.
24. British HIV Association website. UK National Guidelines for HIV Testing 2008. Available: http://www.bhiva.org/hivtesting2008.aspx. Accessed 2014 Apr 2.
25. Gold MR, Siegel J, Russell L, Weinstein M (1996) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
26. Fox J, White PJ, Macdonald N, Weber J, McClure M, et al. (2009) Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 10: 432-438.
27. National Institute for Health and Clinical Excellence (2007) The Guidelines Manual. NICE Public Health Guidance. London, UK: National Institute for Health and Clinical Excellence.
28. Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13: 437-452. (Pubitemid 38660393)
29. Owen D (2009) African migration to the UK. Conference on African Transnational and Return Migration. University of Warwick, Coventry, UK.
30. Stabile M, Thomson S, Allin S, Boyle S, Busse R, et al. (2013) Health care cost containment strategies used in four other high-income countries hold lessons for the United States. Health Aff (Millwood) 32: 643-652.
31. Wilson D, Halperin DT (2008) "Know your epidemic, know your response": a useful approach, if we get it right. Lancet 372: 423-426.
32. Hankins CA, de Zalduondo BO (2010) Combination prevention: a deeper understanding of effective HIV prevention. AIDS 24 Suppl 4: S70-80.
33. Aghaizu A, Brown AE, Nardone A, Gill ON, Delpech VC (2013) HIV in the United Kingdom 2013 Report: Data to End 2012. London, UK: Public Health England.
34. Richter M (2012) Rapid overview of HIV testing in South Africa. Southern African HIV Clinicians' Society Conference. Cape Town, South Africa.
35. Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
36. Justice AC (2010) HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 7: 69-76.
37. Care Quality Commission (2012) The State of Health Care and Adult Social Care in England: An Overview of Key Themes in Care in 2011/12. London, UK: The Stationery Office. Available: http://www.cqc.org.uk/sites/default/files/media/ documents/cqc-soc-201112-final-tag.pdf.
38. Office for National Statistics (ONS) (2011) ONS Population Estimates by Ethnic Group (Experimental), 2002-2009. Available: http://www.ons.gov.uk/ons/ rel/peeg/population-estimates-by-ethnic-group-experimental-/current-estimates/ index.html.
39. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2013) Key statistics on the drug situation in United Kingdom. Available: http://www.emcdda.europa.eu/publications/country-overviews/uk/data-sheet.
40. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2013) 2010 National Report (2009 Data) to the EMCDDA by the Reitox National Focal Point: United Kingdom. New Developments, Trends and In-depth Information on Selected Issues. Available: http://www.emcdda.europa.eu/attachements.cfm/att- 142584-EN-UK-NR2010.pdf.
41. Health Protection Agency (2008) Sexually Transmitted Infections and Men who have Sex with Men in the UK: 2008 Report. London, UK: Health Protection Agency.
42. Office for National Statistics (ONS) (2011) Population estimates for UK, England and Wales, Scotland and Northern Ireland - current datasets: Mid-2010 Population Estimates Analysis Tool, ONS Population Estimates. Available: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates
43. Health Protection Agency (2011) HIV in the United Kingdom: 2011 Report. Health Protection Report. London, UK: Health Protection Agency.
44. Joloza T, Evans J, O'Brien R, Potter-Collins A (2010) Measuring Sexual Identity: An Evaluation Report. Newport, South Wales: Office for National Statistics (ONS).
45. Health Protection Agency (2010) HIV in the United Kingdom: 2010 Report. Health Protection Report. London, UK: Health Protection Agency.
46. Office for National Statistics (2009) Great Britain, Interim Life Tables, 1980-82 to 2007-09. Available: http://www.statistics.gov.uk/StatBase/Product. asp?vlnk=14459.
47. Office for National Statistics (2009) Population Pyramid Datasets. Available: http://www.statistics.gov.uk/populationestimates/flash-pyramid/ default.htm.
48. Hollingsworth TD, Anderson RM, Fraser C (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687-693.
49. Pinkerton SD (2007) How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 21: 1625-1629.
50. Patel P, Mackellar D, Simmons P, Uniyal A, Gallagher K, et al. (2010) Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med 170: 66-74.
51. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879. (Pubitemid 37070272)
52. Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL (2009) Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS 23: 1792-1794.
53. Abbas UL, Anderson RM, Mellors JW (2006) Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J AIDS 41: 632-641.
54. Downs AM, de Vincenzi I (1996) Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 11: 388-395. (Pubitemid 126448572)
55. Kaplan EH, Heimer R (1992) A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 5: 1116-1118.
56. Mastro TD, de Vincenzi I (1996) Probabilities of sexual HIV-1 transmission. AIDS 10 Suppl A: S75-82.
57. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, et al. (1994) The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 5: 570-575. (Pubitemid 24336507)
58. Padian NS, Shiboski SC, Glass SO, Vittinghoff E (1997) Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 146: 350-357.
59. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group. New Engl J Med 342: 921-929. (Pubitemid 30177052)
60. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403-1409. (Pubitemid 40563350)
61. Caceres CF, van Griensven GJ (1994) Male homosexual transmission of HIV-1. AIDS 8: 1051-1061. (Pubitemid 24228700)
62. Jacquez JA, Koopman JS, Simon CP, Longini IM, Jr. (1994) Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 7: 1169-1184.
63. McDaid LM, Li J, Knussen C, Flowers P (2013) Sexually transmitted infection testing and self-reported diagnoses among a community sample of men who have sex with men, in Scotland. Sex Transm Infect 89: 223-230.
64. Carter M (2007) Inconsistent condom use by UK's gay men, with many putting themselves or others at risk of HIV. London: NAM AIDSMAP. Available: http://www.aidsmap.com/Inconsistent-condom-use-by-UKs-gay-men-with-many-putting- themselves-or-others-at-risk-of-HIV/page/1427035/.
65. Health Protection Agency (2013) Unlinked Anonymous Monitoring Survey of People Who Inject Drugs (PWID). London, UK: Health Protection Agency. Available: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HIV/ OverallHIVPrevalence/hivsti-hiv-prev-InjectingDrugUseUAIDU/.
66. Robinson C, Nardone A, Mercer CH, Johnson AM (2011) Sexual health. In: The Health and Social Care Information Centre, editor editors. Health Survey for England, 2010.
67. Dave SS, Fenton KA, Mercer CH, Erens B, Wellings K, et al. (2003) Male circumcision in Britain: findings from a national probability sample survey. Sex Transm Infect 79: 499-500. (Pubitemid 38021418)
68. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298.
69. Desai K, Boily MC, Garnett GP, Masse BR, Moses S, et al. (2006) The role of sexually transmitted infections in male circumcision effectiveness against HIV-insights from clinical trial simulation. Emerg Themes Epidemiol 3: 19.
70. Siegfried N, Muller M, Deeks JJ, Volmink J (2009) Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev: CD003362.
71. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole S, et al. (2006) Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20: 2207-2215. (Pubitemid 44684712)
72. Zaric GS, Barnett PG, Brandeau ML (2000) HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 90: 1100-1111. (Pubitemid 30445365)
73. Wall SD, Olcott EW, Gerberding JL (1991) AIDS risk and risk reduction in the radiology department. AJR Am J Roentgenol 157: 911-991.
74. Zaric GS, Brandeau ML, Barnett PG (2000) Methadone maintenance treatment and HIV prevention: a cost effectiveness analysis. Manage Sci 46: 1013-1031.
75. McElrath K, Chitwood DD, Griffin DK, Comerford M (1994) The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health 84: 1965-1970.
76. National Prospective Monitoring System - HIV Health-Economics Collaboration (NPMS-HHC) (2013) Unpublished data. London.
77. Sadler KE, McGarrigle CA, Elam G, Ssanyu-Sseruma W, Davidson O, et al. (2007) Sexual behaviour and HIV infection in black-Africans in England: results from the Mayisha II survey of sexual attitudes and lifestyles. Sex Transm Infect 83: 523-529. (Pubitemid 350290971)
78. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, et al. (1993) The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13: 89-102. (Pubitemid 23113445)
79. Holtgrave DR, Pinkerton SD (1997) Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immun Defic Syndr 16: 54-62.
80. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, et al. (2006) The effect of diagnosis with HIV infection on health-related quality of life. Qual Life Res 15: 69-82. (Pubitemid 43102473)
81. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, et al. (2002) Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. 22: 27-38.
82. Tengs TO, Lin TH (2002) A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 22: 475-481. (Pubitemid 35334817)
83. Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, et al. (2012) Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One 7: e27830.
84. North West Public Health Observatory (2011) A Review of the Cost-Effectiveness of Individual Level Behavior Change Interventions. Liverpool, UK.
85. National Audit Office (United Kingdom) (2010) Tackling Problem Drug Use. Report by the Comptroller and Auditor General. London: National Audit Office.